3/9 Dissecting the effects of genomic variants on neurobehavioral dimensions in CNVs enriched for neuropsychiatric disorders

3/9 剖析基因组变异对富含神经精神疾病的 CNV 中神经行为维度的影响

• 批准号: 10083537
• 负责人: CARRIE E BEARDEN
• 金额: $ 7.19万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-06-15 至 2024-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10083537
• 关键词: 16p11.2; 22q11.2; Affect; Algorithms; Anxiety; Anxiety Disorders; Architecture; Attention; Attention deficit hyperactivity disorder; Attentional deficit; Brain; Categories; Clinical; Cognition; Cognitive; Collaborations; Complement; Complex; Computing Methodologies; Copy Number Polymorphism; Custom; Data; Data Analytics; Development; Developmental Course; Developmental Delay Disorders; Diagnosis; Dimensions; Disease; Early Intervention; Emotional; Emotions; Environment; Environmental Risk Factor; Evaluation; Family; Family member; Genes; Genetic; Genetic Determinism; Genetic Predisposition to Disease; Genetic study; Genomics; Goals; Heterogeneity; Hyperactive behavior; Individual; Institution; Intellectual functioning disability; International; Knowledge; Lead; Literature; Longevity; Measures; Memory; Mental Depression; Mind; Modeling; Molecular; National Institute of Mental Health; Nature; Neurocognition; Online Systems; Outcome; Patients; Phenotype; Population; Positioning Attribute; Psychiatric Diagnosis; Psychopathology; Psychotic Disorders; Public Domains; Recurrence; Resources; Risk; Sampling; Schizophrenia; Social Behavior; Specificity; Structure; Symptoms; Syndrome; Variant; Work; adverse outcome; autism spectrum disorder; base; brain behavior; case control; clinical Diagnosis; clinical phenotype; clinical predictors; cohort; experience; externalizing behavior; genetic architecture; genetic pedigree; genetic variant; genome sequencing; genome wide association study; genomic locus; interest; large scale data; neurobehavioral; neuropsychiatric disorder; neuropsychiatry; personalized approach; phenomics; polygenic risk score; processing speed; prospective; rare genetic disorder; rare variant; recruit; risk prediction model; social; symptomatology; theories; tool; whole genome

PROJECT SUMMARY The International Consortium on Brain and Behavior Copy Number Variants (IBBC-CNVs) is a collaborative effort of 9 institutions with complementary experience and expertise in phenomics and genomics. The 22q11.2 and 16p11.2 loci are associated with significant risk for neuropsychiatric disorders across the lifespan. The clinical presentations are heterogeneous, manifesting in a range of developmental neuropsychiatric disorders, including Attention Deficit Hyperactivity, Anxiety, Autism Spectrum, and Psychosis Spectrum Disorders. Taking a `genetics first' approach of ascertaining patients based on known, homogeneous genetic etiologies will allow us to overcome barriers posed by the genetic and phenotypic complexity of idiopathic developmental neuropsychiatric disorders. We postulate that CNVs exert a large main effect on psychopathology, but the nature and degree of psychopathology observed in CNV carriers is multifactorial, with contributions from additional rare and common genetic variants, as well as environmental factors. Therefore, dissecting the effects of major CNV hits as well as additional rare and common variants on dimensional measures of psychopathology can elucidate the combined contribution of genetic mechanisms to psychiatric conditions and build models of risk prediction. Notably, the presentation and course of psychopathology in the CNVs resemble these features in idiopathic disorders. Therefore, beyond the specific genetic syndromes investigated, such a cross-CNV effort will identify convergent risk mechanisms for developmental neuropsychiatric disorders that are of relevance to the broader population. We propose to dissect dimensional measures of psychosis, social-emotional processing and neurocognition, and their genetic and environmental modifiers, to elucidate the architecture of risk for neuropsychiatric disorders in CNV carriers. Prospective evaluation with dimensional measures relevant to neuropsychiatric disorders will be applied to a cohort of 2000 individuals with 22q11.2 and 16p11.2 deletions and duplications (500 per group) and their relatives as feasible. In addition, categorical psychiatric diagnoses will be assessed in CNV carriers. Recruitment for prospective phenotyping will leverage existing large cohorts that carry these reciprocal CNVs, many of whom have already been ascertained and characterized with a range of phenotypic measures. New whole genome sequencing (WGS) will be performed in CNV carriers that have not yet been sequenced. We will also utilize existing genetic data from the largest available case-control samples diagnosed with SZ, ASD, and ADHD in the PGC. Finally, analysis of common variants for a subset of family members will allow us to complement our primary analysis by exploring models of complex genetic inheritance in extended pedigrees that carry CNVs. Our ability to conceive such a large scale study capitalizes on our existing successful collaborations, complementary expertise, and institutional commitments to achieve these goals.

项目摘要 脑和行为拷贝数变异国际联盟（IBBC-CNVs）是一个合作组织， 在表型组学和基因组学方面具有互补经验和专门知识的9个机构的努力。22q11.2 16p11.2位点与终生神经精神疾病的显著风险相关。的 临床表现是异质性的，表现为一系列发育性神经精神障碍， 包括注意力缺陷多动、焦虑、自闭症谱系和精神病谱系障碍。以 根据已知的、同质的遗传病因确定患者的“遗传学优先”方法将允许 我们克服特发性发育障碍的遗传和表型复杂性所构成的障碍， 神经精神疾病。我们假设CNVs对精神病理学有很大的主要影响，但是 在CNV携带者中观察到的精神病理学的性质和程度是多因素的， 其他罕见和常见的遗传变异，以及环境因素。因此，解剖 主要CNV命中以及额外的罕见和常见变异对 精神病理学可以阐明遗传机制对精神疾病的综合作用， 建立风险预测模型。值得注意的是，CNVs中精神病理学的表现和过程类似于 这些特发性疾病的特征。因此，除了所研究的特定遗传综合征之外， 跨CNV的努力将确定发育性神经精神障碍的会聚风险机制， 与更广泛的人群有关。 我们建议剖析精神病的维度测量，社会情绪处理和 神经认知及其遗传和环境修饰剂，以阐明 CNV携带者的神经精神障碍。前瞻性评价，尺寸测量相关 神经精神疾病将应用于2000名22q11.2和16p11.2缺失的个体的队列 和重复（每组500人）及其亲属作为可行。此外，精神病的分类诊断 将在CNV携带者中进行评估。前瞻性表型分析的招募将利用现有的大型队列 携带这些相互的CNV，其中许多已经被确定并表征为 一系列表型测量。新的全基因组测序（WGS）将在CNV携带者中进行， 尚未被测序。我们还将利用现有的遗传数据，从最大的可用病例对照 在PGC中诊断为SZ、ASD和ADHD的样本。最后，分析了一个子集的常见变体， 家庭成员将使我们能够通过探索复杂的遗传模型来补充我们的初步分析。 携带CNVs的扩展家系中的遗传。我们构思如此大规模研究的能力 我们现有的成功合作，互补的专业知识和机构承诺，以实现 这些目标。